![\"\"](\"https:\/\/i-base.info\/htb\/wp-content\/uploads\/2026\/02\/CROI-page-banner-300x58.png\")
<\/p>\n<\/p>\n
Simon Collins, HIV i-Base<\/strong><\/p>\n Results from an independent study in macaques showed that although implants that slow-released a low dose of islatravir protected animals against rectal exposure to wild-type SHIV, it failed to protect against SHIV with the M184V mutation. [1]<\/strong><\/p>\n This study is important because although islatravir is no longer being developed as PrEP, it is structurally very similar to the investigational NRTTI MK-8527, which is now entering phase 3 studies as a once-monthly oral formulation of PrEP.<\/p>\n The results were presented by Charles Dobard from the US CDC in Atlanta and colleagues.<\/p>\n The study included 11 animals that were exposed rectally to either wild-type (n=6) or SHIV with M184V (n=5), twice weekly, for up to four weeks, and compared to untreated macaques. No infections occurred after exposures to wild-type SIV compared to 4 out of 5 animals that were infected after a median of three exposure to M184V. The difference was highly statistically significant (p=0.0091).<\/p>\n However, even though it is a similar structured compound, the results are not thought likely to have clinical significance for the development of MK-8527 because of the very low incidence of M184V in the general population (in most settings).<\/p>\n The practical implications from this study were also difficult to interpret because the study increased the infectiousness of the SHIV challenge four-fold in order to adjust for the reduced viral fitness associated with the M184V mutation.<\/p>\n Also, M184V is not commonly reported in viral transmission studies because in the absence of drug pressure it usually quickly reverts to wild-type virus.<\/p>\n Reference<\/p>\n Simon Collins, HIV i-Base Results from an independent study in macaques showed that although implants that slow-released a low dose of islatravir protected animals against rectal exposure to wild-type SHIV, it failed to protect against SHIV with the M184V mutation. …<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,10,36],"tags":[346],"class_list":["post-53297","post","type-post","status-publish","format-standard","hentry","category-conference-reports","category-transmission-and-prevention","category-drug-resistance","tag-croi-2026"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/53297","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=53297"}],"version-history":[{"count":8,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/53297\/revisions"}],"predecessor-version":[{"id":53540,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/53297\/revisions\/53540"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=53297"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=53297"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=53297"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}\n